Phase 2 Endometrial Cancer Trial, Recruiting NCT07439497 Sponsor: Samsung Medical Center Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 2 Endometrial Cancer Trial, Recruiting

NCT07439497
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with cervical cancer confirmed by a laboratory tissue test, specifically one of these types: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
  • People whose cancer has been staged as FIGO stage IIB, III, or IVA (using the 2018 staging system), meaning the cancer has spread beyond the cervix but has not reached distant parts of the body
  • People who have a measurable tumour visible on a pelvic MRI scan taken within the 30 days before treatment begins
  • People aged 20 years or older
  • People who are generally well enough to carry out daily activities with little or no limitation (known in medical terms as ECOG performance status 0–1; confirm with trial site if unsure how this applies)
  • People whose blood test results show the bone marrow is producing enough blood cells — including white blood cells, infection-fighting cells (neutrophils), platelets, and red blood cells — at levels meeting the trial's minimum thresholds
  • People whose kidneys are functioning well enough, as shown by a blood test measuring creatinine levels below a certain threshold
  • People who are able to give written consent to participate in the trial

Who may not be able to join:

  • People whose cancer has spread to distant parts of the body (distant metastasis)
  • People who have previously had radiotherapy to the pelvic area
  • People who have already received chemotherapy or combined chemotherapy and radiotherapy as a main treatment for their cervical cancer diagnosis
  • People who have had surgery to treat their current cervical cancer
  • People who had a cone biopsy or a procedure called LEEP (a type of electrical loop excision of cervical tissue) before starting radiotherapy
  • People who are not well enough to receive combined chemotherapy and radiotherapy treatment
  • People who have had another active cancer (other than certain low-risk cancers such as carcinoma in situ of the cervix, basal cell skin cancer, or superficial bladder cancer) within the past 3 years, or whose previous cancer came back within 3 years after treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +82-10-9933-2616

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
9 December 2025
Est. completion
30 May 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Tumor Volume Redution Rate (TVRR) at 1 month after completion of treatment based on MRI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov